GlaxoSmithKline (NYSE:GSK) CFO Simon Dingemans is among those at the JP Morgan Global Healthcare Conference this week in San Francisco and he took some time out to discuss respiratory drug candidate Relovair, which the company said would be submitted this year to U.S. and European regulators for approval.

Bloomberg Television in this video interview asked Dingemans about “disappointing results” but the query didn’t go far enough. 

(Read more about the trial results here.)

Dingemans said that the results weren’t disappointing and that the drug candidate, which was seen as a successor to blockbuster drug Advair, is part of a drug pipeline of forthcoming GSK respiratory products.

“That has always been the strategy and thinking about moving on from Advair is bringing a pipeline and a portfolio to the approach, not just one product in isolation,” Dingemans said.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.